{"id":3094,"date":"2016-08-11T11:53:18","date_gmt":"2016-08-11T15:53:18","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/"},"modified":"2026-09-24T00:10:02","modified_gmt":"2026-09-24T04:10:02","slug":"gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/","title":{"rendered":"GenSight Biologics annonce la mise en \u0153uvre d\u2019un contrat  de liquidit\u00e9 avec Oddo &#038; Cie"},"content":{"rendered":"\n<strong>Paris, le 11 ao\u00fbt\u00a0 2016 \u2013<\/strong> GenSight Biologics (Euronext : SIGHT, FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce avoir confi\u00e9 \u00e0 Oddo &amp; Cie, \u00e0 compter de ce jour, la mise en \u0153uvre d\u2019un contrat de liquidit\u00e9 conforme \u00e0 la Charte de d\u00e9ontologie \u00e9tablie par l\u2019Association fran\u00e7aise des march\u00e9s financiers (AMAFI) et approuv\u00e9e par d\u00e9cision de l&rsquo;Autorit\u00e9 des march\u00e9s financiers (AMF) du 21 mars 2011.\n\nPour la mise en \u0153uvre de ce contrat, les moyens suivants ont \u00e9t\u00e9 affect\u00e9s au compte de liquidit\u00e9 :\n<ul>\n \t<li>300 000 \u20ac en esp\u00e8ces<\/li>\n<\/ul>\n<h2>\u00c0 propos \u00a0de GenSight Biologics<\/h2>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates -formes technologiques : le ciblage mitochondrial (Mitochondrial Targeting Sequence, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intravitr\u00e9enne dans chaque \u0153il.\n","protected":false},"excerpt":{"rendered":"<p>Paris, le 11 ao\u00fbt\u00a0 2016 \u2013 GenSight Biologics (Euronext : SIGHT, FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce avoir confi\u00e9 \u00e0 Oddo &amp; Cie, \u00e0 compter de ce jour, la mise [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[],"class_list":["post-3094","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics annonce la mise en \u0153uvre d\u2019un contrat de liquidit\u00e9 avec Oddo &amp; Cie - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics annonce la mise en \u0153uvre d\u2019un contrat de liquidit\u00e9 avec Oddo &amp; Cie - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, le 11 ao\u00fbt\u00a0 2016 \u2013 GenSight Biologics (Euronext : SIGHT, FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce avoir confi\u00e9 \u00e0 Oddo &amp; Cie, \u00e0 compter de ce jour, la mise [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2016-08-11T15:53:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:10:02+00:00\" \/>\n<meta name=\"author\" content=\"editeur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"editeur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2016\\\/08\\\/11\\\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2016\\\/08\\\/11\\\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\\\/\"},\"author\":{\"name\":\"editeur\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"headline\":\"GenSight Biologics annonce la mise en \u0153uvre d\u2019un contrat de liquidit\u00e9 avec Oddo &#038; Cie\",\"datePublished\":\"2016-08-11T15:53:18+00:00\",\"dateModified\":\"2026-09-24T04:10:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2016\\\/08\\\/11\\\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\\\/\"},\"wordCount\":323,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2016\\\/08\\\/11\\\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2016\\\/08\\\/11\\\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\\\/\",\"name\":\"GenSight Biologics annonce la mise en \u0153uvre d\u2019un contrat de liquidit\u00e9 avec Oddo & Cie - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2016-08-11T15:53:18+00:00\",\"dateModified\":\"2026-09-24T04:10:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2016\\\/08\\\/11\\\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2016\\\/08\\\/11\\\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2016\\\/08\\\/11\\\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics annonce la mise en \u0153uvre d\u2019un contrat de liquidit\u00e9 avec Oddo &#038; Cie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\",\"name\":\"editeur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"caption\":\"editeur\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics annonce la mise en \u0153uvre d\u2019un contrat de liquidit\u00e9 avec Oddo & Cie - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics annonce la mise en \u0153uvre d\u2019un contrat de liquidit\u00e9 avec Oddo & Cie - GenSight Biologics","og_description":"Paris, le 11 ao\u00fbt\u00a0 2016 \u2013 GenSight Biologics (Euronext : SIGHT, FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce avoir confi\u00e9 \u00e0 Oddo &amp; Cie, \u00e0 compter de ce jour, la mise [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/","og_site_name":"GenSight Biologics","article_published_time":"2016-08-11T15:53:18+00:00","article_modified_time":"2026-09-24T04:10:02+00:00","author":"editeur","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"editeur","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/"},"author":{"name":"editeur","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"headline":"GenSight Biologics annonce la mise en \u0153uvre d\u2019un contrat de liquidit\u00e9 avec Oddo &#038; Cie","datePublished":"2016-08-11T15:53:18+00:00","dateModified":"2026-09-24T04:10:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/"},"wordCount":323,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/","name":"GenSight Biologics annonce la mise en \u0153uvre d\u2019un contrat de liquidit\u00e9 avec Oddo & Cie - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2016-08-11T15:53:18+00:00","dateModified":"2026-09-24T04:10:02+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2016\/08\/11\/gensight-biologics-annonce-la-mise-en-oeuvre-dun-contrat-de-liquidite-avec-oddo-cie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics annonce la mise en \u0153uvre d\u2019un contrat de liquidit\u00e9 avec Oddo &#038; Cie"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a","name":"editeur","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","caption":"editeur"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3094"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3094\/revisions"}],"predecessor-version":[{"id":6396,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3094\/revisions\/6396"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3094"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3094"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3094"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3094"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}